Netherlands· NL-bf9602a1f0a2

Inovelon 400 mg, filmomhulde tabletten

A rufinamide product containing rufinamide, registered in Netherlands by Eisai GmbH. The same ATC class is registered in 17 of our 19 countries.

ATC N03AF03

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about rufinamideAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Rufinamide is registered in 17 of 19 countries.

Countries holding a registration under ATC N03AF03 (rufinamide), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
10 of them publish a price we can compare per daily dose

Search rufinamide products by name

Rufinamide · ATC N03AF03

17 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Icelandprice
Ireland
Italyprice
Japan
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rufinamide costs, country by country.

Normalised to the WHO defined daily dose (1.4 g), the median price runs from $7.83 in Switzerland to $12.24 in Italy — a ×1.6 gap.

3 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Rufinamide · price per daily dose (1.4 g)

USD · FX 28 Sept 2026

IT Italy$12.24
FR France$8.57
CH Switzerland$7.83

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: RUFINAMIDE
Manufacturer: Eisai GmbH
Country: Netherlands (NL)
ATC code: N03AF03
ATC class: Rufinamide
Defined daily dose: 1.4 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/06/378

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

238 interactions on record for rufinamide.

Graded by severity as the source publishes them — 232 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check rufinamide against other medicines How interaction checks work

Rufinamide · interactions on record

238 records

232 moderate
6 minor

Most severe, free to view

MetoclopramideA03FA01moderate
OndansetronA04AA01moderate
GranisetronA04AA02moderate
ThiethylperazinA04AB03moderate

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rufinamide in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rufinamide products

Authorised across Europe · EMA

The same active substance is authorised in 6 EEA countries. Names it is sold under:

Germany · Rufinamid Actrevo, Rufinamid Micro Labs
France · Rufinamide Actrevo, Rufinamide Medipha
United Kingdom (Northern Ireland) · Rufinamide, Rufinamide Brown & Burk
Iceland · Inovelon
Liechtenstein · Inovelon
Norway · Inovelon

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/19fab1a5-8885-491f-8166-d7d0ca515160
GET /v1/drugs/19fab1a5-8885-491f-8166-d7d0ca515160?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/inovelon-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Rufinamide",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp72915",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "HYPROMELLOSE (E 464)",
    "IJZEROXIDE ROOD  (E 172)",
    "LACTOSE 1-WATER",
    "MACROGOL 8000",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MAÏSZETMEEL",
    "NATRIUMLAURILSULFAAT",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "RUFINAMIDE"
  ],
  "leaflet_url": null,
  "authorised_at": "2007/01/16",
  "procedure_number": "EMEA/H/C/000660",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/06/378",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about rufinamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console